“As we work to advance our lead candidate, IMR-687, for people living with sickle cell disease and beta-thalassemia, we also recognize the responsibility and obligation we have to support and positively impact the lives of the patient communities around us. In 2020, we formalized this commitment by creating the Real Impact program, an important initiative which aligns with our vision of making a meaningful difference for patients, their families and the local communities affected by these rare blood disorders.
We are proud of the effect that the Real Impact program has already made on the health and lives of patients and their families through resources, education, information and support.
Response to the Real Impact grant program was particularly overwhelming in 2020, our first year. With the additional burden the COVID-19 pandemic has placed on those affected by rare blood disorders, we took comfort in knowing those grants have provided a measure of relief to community-based organizations doing vital work for patients and their families.
We look forward to reinstituting the grant program in 2021 with even more funding allocated to support community-based organizations’ initiatives.”
Rahul Ballal, CEO